Medical Condition News

RSS

Happy marriage may help prevent fatal strokes in men: Study

"Love and marriage," sang philosopher Frank Sinatra, "is an institute you can't disparage." Especially, a new Tel Aviv University study suggests, when a happy marriage may help to prevent fatal strokes in men.

9 Apr 2010

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.

9 Apr 2010

Researchers make dramatic strides in understanding and treating leukemia

In the past decade, researchers have made dramatic strides in understanding and treating leukemia, according to the April issue of Mayo Clinic Health Letter.

9 Apr 2010

Idaho man fourth in country to receive Levacor- VAD implant

After receiving only the fourth U.S. implant of a new-generation, Utah-made ventricular assist (VAD ) device, an Idaho man with heart failure is looking forward to resuming an active life following an operation on March 17 at University of Utah Hospital.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Bill to stop under 18s using sunbeds passed by the House of Lords

The private member's bill to protect children and teenagers from the dangers of sunbeds was passed today by the House of Lords after Cancer Research UK's campaign.

9 Apr 2010

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

9 Apr 2010

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

As overall cancer rates are declining in the United States, thyroid cancer counters the trend. It's being diagnosed more frequently, especially in women. Women are three times more likely than men to develop thyroid cancer.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.

9 Apr 2010

Dangerous agitations: Nicotine replacement therapy needs to be tested in ICU setting

Nicotine withdrawal can cause dangerous agitation in intensive care patients. Researchers writing in BioMed Central's open access journal Critical Care found that, compared to non-smokers, agitated smokers were more likely to accidentally remove tubes and catheters, require supplemental sedative, analgesic or anti-psychotic medications, or need physical restraints.

9 Apr 2010

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia's first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world's 850th recipient of the Total Artificial Heart.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

ReVision Optics, a leading company in the research, development and manufacture of custom optical products to correct and maintain vision, announced today that it has begun its US clinical trial of the PresbyLens® corneal inlay. The clinical trial will evaluate the PresbyLens® corneal inlay for the correction of presbyopia, the age-related loss of near vision. The study began on April 6th with the treatment of three subjects by clinical investigator Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

Near death experiences (NDEs), reported to include sensations such as life flashing before the eyes, feelings of peace and joy, and apparent encounters with mystical entities, may be caused by raised levels of carbon dioxide in the blood. Researchers writing in BioMed Central's open access journal Critical Care investigated the unexplained events in 52 cardiac arrest patients.

8 Apr 2010

WTC FDNY Rescue Workers have not recovered normal lung function, yet

A study of nearly 13,000 rescue workers from the Fire Department of the City of New York (FDNY) shows that the significant proportion who suffered acute lung damage after exposure to World Trade Center (WTC) dust have not recovered normal lung function in the years since the September 11, 2001 terrorist attacks.

8 Apr 2010

Medical Condition News

Happy marriage may help prevent fatal strokes in men: Study

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Researchers make dramatic strides in understanding and treating leukemia

Idaho man fourth in country to receive Levacor- VAD implant

Nanotechnology-based vaccine cures mice with type 1 diabetes

Bill to stop under 18s using sunbeds passed by the House of Lords

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Dangerous agitations: Nicotine replacement therapy needs to be tested in ICU setting

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

Æterna Zentaris commences perifosine Phase 3 registration trial

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

WTC FDNY Rescue Workers have not recovered normal lung function, yet

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News